Search research articles
Contact Us
Filters
Showing results (61-70 of 85) with videos related to
Page
of 9
Sort By:
Journal of Psychiatric Research
|
May 22, 2010
Tolerability of the dexamethasone-corticotropin releasing hormone test in major depressive disorder
Boadie W Dunlop, Yara Betancourt, Elisabeth B Binder, et al.
Depression and Anxiety
|
September 28, 2018
Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse
Mary E Kelley, Boadie W Dunlop, Charles B Nemeroff, et al.
Archives of General Psychiatry
|
September 3, 2008
Family-focused treatment for adolescents with bipolar disorder: results of a 2-year randomized trial
David J Miklowitz, David A Axelson, Boris Birmaher, et al.
Journal of Affective Disorders
|
January 16, 2025
Metabolomics signatures of serotonin reuptake inhibitor (escitalopram), serotonin norepinephrine reuptake inhibitor (duloxetine) and cognitive-behavioral therapy on key neurotransmitter pathways in major depressive disorder
Sudeepa Bhattacharyya, Siamak MahmoudianDehkordi, Matthew J Sniatynski, et al.
Medrxiv : the Preprint Server for Health Sciences
|
April 18, 2024
Metabolomics Signatures of serotonin reuptake inhibitor (Escitalopram), serotonin norepinephrine reuptake inhibitor (Duloxetine) and Cognitive Behavior Therapy on Key Neurotransmitter Pathways in Major Depressive Disorder
Sudeepa Bhattacharyya, Siamak MahmoudianDehkordi, Matthew J Sniatynski, et al.
Psychosomatic Medicine
|
September 12, 2007
Exercise and pharmacotherapy in the treatment of major depressive disorder
James A Blumenthal, Michael A Babyak, P Murali Doraiswamy, et al.
Frontiers in Neuroscience
|
October 2, 2019
Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment
Sudeepa Bhattacharyya, Boadie W Dunlop, Siamak Mahmoudiandehkordi, et al.
The American Journal of Psychiatry
|
December 16, 2017
Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein
Chloe P O'Connell, Andrea N Goldstein-Piekarski, Charles B Nemeroff, et al.
Scientific Reports
|
October 26, 2021
Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature
Christopher R Brydges, Oliver Fiehn, Helen S Mayberg, et al.
Neuron
|
August 28, 2018
Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response
Shariful A Syed, Eléonore Beurel, David A Loewenstein, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 85) with videos related to
Sort By:
Page
of 9
Journal of Psychiatric Research
|
May 22, 2010
Tolerability of the dexamethasone-corticotropin releasing hormone test in major depressive disorder
Boadie W Dunlop, Yara Betancourt, Elisabeth B Binder, et al.
Depression and Anxiety
|
September 28, 2018
Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse
Mary E Kelley, Boadie W Dunlop, Charles B Nemeroff, et al.
Archives of General Psychiatry
|
September 3, 2008
Family-focused treatment for adolescents with bipolar disorder: results of a 2-year randomized trial
David J Miklowitz, David A Axelson, Boris Birmaher, et al.
Journal of Affective Disorders
|
January 16, 2025
Metabolomics signatures of serotonin reuptake inhibitor (escitalopram), serotonin norepinephrine reuptake inhibitor (duloxetine) and cognitive-behavioral therapy on key neurotransmitter pathways in major depressive disorder
Sudeepa Bhattacharyya, Siamak MahmoudianDehkordi, Matthew J Sniatynski, et al.
Medrxiv : the Preprint Server for Health Sciences
|
April 18, 2024
Metabolomics Signatures of serotonin reuptake inhibitor (Escitalopram), serotonin norepinephrine reuptake inhibitor (Duloxetine) and Cognitive Behavior Therapy on Key Neurotransmitter Pathways in Major Depressive Disorder
Sudeepa Bhattacharyya, Siamak MahmoudianDehkordi, Matthew J Sniatynski, et al.
Psychosomatic Medicine
|
September 12, 2007
Exercise and pharmacotherapy in the treatment of major depressive disorder
James A Blumenthal, Michael A Babyak, P Murali Doraiswamy, et al.
Frontiers in Neuroscience
|
October 2, 2019
Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment
Sudeepa Bhattacharyya, Boadie W Dunlop, Siamak Mahmoudiandehkordi, et al.
The American Journal of Psychiatry
|
December 16, 2017
Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein
Chloe P O'Connell, Andrea N Goldstein-Piekarski, Charles B Nemeroff, et al.
Scientific Reports
|
October 26, 2021
Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature
Christopher R Brydges, Oliver Fiehn, Helen S Mayberg, et al.
Neuron
|
August 28, 2018
Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response
Shariful A Syed, Eléonore Beurel, David A Loewenstein, et al.
Page
of 9